Edward Tenthoff Analyst Performance

Analyst at Piper Sandler

Edward Tenthoff is a stock analyst at Piper Sandler focused in the medical sector, covering 55 publicly traded companies. Over the past year, Edward Tenthoff has issued 12 stock ratings, including and buy recommendations. While full access to Edward Tenthoff's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Edward Tenthoff's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 236 Last 10 Years
Buy Recommendations: 79.82% 178 Buy Ratings
Companies Covered: 55 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	79.8%	178 ratings
Hold	18.4%	41 ratings
Sell	1.8%	4 ratings

Out of 223 total stock ratings issued by Edward Tenthoff at Piper Sandler, the majority (79.8%) have been Buy recommendations, followed by 18.4% Hold and 1.8% Sell.

Best & Worst Calls

Best Call
000000.0%
PTI
Dec 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
VSAR
Sep 2017
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.7% of companies on NASDAQ	51 companies
OTCMKTS	3.6% of companies on OTCMKTS	2 companies
NYSE	3.6% of companies on NYSE	2 companies

Edward Tenthoff, an analyst at Piper Sandler, currently covers 55 companies listed on NASDAQ, OTCMKTS and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 51 companies	92.7%
	Miscellaneous 2 companies	3.6%
	Energy 1 company	1.8%
	Transportation 1 company	1.8%

Edward Tenthoff of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on and Energy companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 26 companies	47.3%
PHARMACEUTICAL PREPARATIONS 13 companies	23.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 5 companies	9.1%
MED - DRUGS 3 companies	5.5%
Miscellaneous 2 companies	3.6%
BIOTECHNOLOGY 2 companies	3.6%
MED PRODUCTS 1 company	1.8%
MED INSTRUMENTS 1 company	1.8%
SOLAR 1 company	1.8%
TRANS - AIRLINE 1 company	1.8%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$392.24	$449.00	Overweight
NXTC NextCure	7/15/2025	Set Price Target	$4.85	$15.00	Overweight
CAPR Capricor Therapeutics	7/11/2025	Reiterated Rating	$7.94	$20.00	Overweight
INO Inovio Pharmaceuticals	7/9/2025	Initiated Coverage	$1.34	$5.00	Overweight
CRSP CRISPR Therapeutics	6/27/2025	Reiterated Rating	$47.45	$105.00	Overweight
BMEA Biomea Fusion	6/3/2025	Initiated Coverage	$1.55	$7.00	Overweight
FULC Fulcrum Therapeutics	5/29/2025	Reiterated Rating	$6.90	$9.00	Overweight
ITOS iTeos Therapeutics	5/14/2025	Reiterated Rating	$7.33	$12.00	Overweight
ARVN Arvinas	5/2/2025	Reiterated Rating	$7.02	$14.00	Overweight
IPSC Century Therapeutics	3/20/2025	Lower Price Target	$0.54	$2.00	Overweight
DYN Dyne Therapeutics	2/28/2025	Lower Price Target	$13.17	$48.00	Overweight
MESO Mesoblast	2/7/2025	Reiterated Rating	$19.85	$24.00	Overweight

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.